Latest Clinical Validation News

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

HeraMED Limited has raised $1.98 million through a discounted share placement to fund its digital maternity care platform's commercial growth across the US, Australia, and Europe.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.